Susan E Krown1. 1. AIDS Malignancy Consortium, c/o The EMMES Corporation, Rockville, Maryland, USA. krowns@mskcc.org
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize recent published literature on treatment of AIDS-associated Kaposi sarcoma, the most common HIV-associated malignancy and a leading cancer diagnosis in sub-Saharan Africa (SSA), and to highlight the challenges faced in treating Kaposi sarcoma in this resource-limited environment. RECENT FINDINGS: There are few prospective clinical trials for Kaposi sarcoma treatment in SSA, along with a relatively poor cancer treatment infrastructure, leading to late diagnosis and poor access to therapy. The only prospectively randomized trial of chemotherapy compared antiretroviral therapy (HAART) alone to HAART with combination chemotherapy with doxorubicin, bleomycin and vincristine (ABV), and documented a significantly higher rate of tumor regression for the combination along with improvement in quality of life and no adverse effects on HIV control. Other studies suggest that gemcitabine may be an active second-line chemotherapeutic agent after failure of HAART and ABV and suggest that AIDS-associated Kaposi sarcoma in children may respond well to HAART with chemotherapy. There are also (primarily retrospective) data suggesting a beneficial effect of HAART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as a manifestation of immune reconstitution inflammatory syndrome. SUMMARY: Opportunities and need exist for prospective research to establish evidence-based guidelines for the most effective treatments for Kaposi sarcoma in SSA.
PURPOSE OF REVIEW: The purpose of this review is to summarize recent published literature on treatment of AIDS-associated Kaposi sarcoma, the most common HIV-associated malignancy and a leading cancer diagnosis in sub-Saharan Africa (SSA), and to highlight the challenges faced in treating Kaposi sarcoma in this resource-limited environment. RECENT FINDINGS: There are few prospective clinical trials for Kaposi sarcoma treatment in SSA, along with a relatively poor cancer treatment infrastructure, leading to late diagnosis and poor access to therapy. The only prospectively randomized trial of chemotherapy compared antiretroviral therapy (HAART) alone to HAART with combination chemotherapy with doxorubicin, bleomycin and vincristine (ABV), and documented a significantly higher rate of tumor regression for the combination along with improvement in quality of life and no adverse effects on HIV control. Other studies suggest that gemcitabine may be an active second-line chemotherapeutic agent after failure of HAART and ABV and suggest that AIDS-associated Kaposi sarcoma in children may respond well to HAART with chemotherapy. There are also (primarily retrospective) data suggesting a beneficial effect of HAART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as a manifestation of immune reconstitution inflammatory syndrome. SUMMARY: Opportunities and need exist for prospective research to establish evidence-based guidelines for the most effective treatments for Kaposi sarcoma in SSA.
Authors: Freddy Sitas; D Max Parkin; Mike Chirenje; Lara Stein; Raymond Abratt; Henry Wabinga Journal: Lancet Oncol Date: 2008-08 Impact factor: 41.316
Authors: Soren Gantt; Abel Kakuru; Anna Wald; Victoria Walusansa; Lawrence Corey; Corey Casper; Jackson Orem Journal: Pediatr Blood Cancer Date: 2010-05 Impact factor: 3.167
Authors: Charles L M Olweny; Margaret Borok; Ivy Gudza; Jennifer Clinch; Mary Cheang; Clem F Kiire; Lorraine Levy; David Otim-Oyet; Joseph Nyamasve; Harvey Schipper Journal: Int J Cancer Date: 2005-02-10 Impact factor: 7.396
Authors: Lisa M Butler; Grant Dorsey; Wolfgang Hladik; Philip J Rosenthal; Christian Brander; Torsten B Neilands; Georgina Mbisa; Denise Whitby; Photini Kiepiela; Anisa Mosam; Similo Mzolo; Sheila C Dollard; Jeffrey N Martin Journal: J Infect Dis Date: 2009-08-01 Impact factor: 5.226
Authors: Emilio Letang; Jose M Almeida; Jose M Miró; Edgar Ayala; Irene E White; Carla Carrilho; Rui Bastos; Tacilta Nhampossa; Clara Menéndez; Thomas B Campbell; Pedro L Alonso; Denise Naniche Journal: J Acquir Immune Defic Syndr Date: 2010-04 Impact factor: 3.731
Authors: E Mwinjiwa; P Isaakidis; R Van den Bergh; A D Harries; K D Bezanson; T Beyene; C Thompson; M Joshua; H Akello; M van Lettow Journal: Public Health Action Date: 2013-06-21
Authors: Mark N Polizzotto; Thomas S Uldrick; Kathleen M Wyvill; Karen Aleman; Cody J Peer; Margaret Bevans; Irini Sereti; Frank Maldarelli; Denise Whitby; Vickie Marshall; Priscila H Goncalves; Vikram Khetani; William D Figg; Seth M Steinberg; Jerome B Zeldis; Robert Yarchoan Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Michael E Herce; Noel Kalanga; Emily B Wroe; James W Keck; Felix Chingoli; Listern Tengatenga; Satish Gopal; Atupere Phiri; Bright Mailosi; Junior Bazile; Jason A Beste; Shekinah N Elmore; Jonathan T Crocker; Jonas Rigodon Journal: J Int AIDS Soc Date: 2015-05-29 Impact factor: 5.396
Authors: Albert A Mwafongo; Nora E Rosenberg; Wingston Ng'ambi; Alexandra B Werner; William M Garneau; Joe Gumulira; Sam Phiri; Mina C Hosseinipour Journal: PLoS One Date: 2014-03-14 Impact factor: 3.240
Authors: Pauline E Chugh; Sang-Hoon Sin; Sezgin Ozgur; David H Henry; Prema Menezes; Jack Griffith; Joseph J Eron; Blossom Damania; Dirk P Dittmer Journal: PLoS Pathog Date: 2013-07-18 Impact factor: 6.823